<DOC>
	<DOC>NCT00646516</DOC>
	<brief_summary>The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.</brief_summary>
	<brief_title>Gemini Symbicort pMDI</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Diagnosis of asthma Baseline lung function tests as determined by protocol. Required and received treatment with inhaled corticosteroids and/or lung treatments specified in the protocol within timeframe and doses specified in protocol. Severe asthma Has required treatment with any noninhaled corticosteroid within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with betablockers Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>inhaled corticosteroids</keyword>
	<keyword>Symbicort</keyword>
	<keyword>budesonide/formoterol</keyword>
	<keyword>budesonide</keyword>
</DOC>